-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target

Benzinga·04/13/2026 11:43:36
Listen to the news
BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains $40 price target.